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The main aim of this multicentre prospective study was to determine the clinical value of
SonoVue administration for the characterisation of focal liver lesions incidentally
detected in oncological or cirrhotic patients.
Eight hundred and seventy four consecutive patients with 1034 nodules (diameter between
5 and 100 mm) not fully characterised by conventional US or previous single-phase CT-scan
were imaged using real-time contrast-enhanced scanning after intravenous injection of
2.4 ml of SonoVue Blinded off-site assessment was conducted to evaluate the diagnostic
performance of contrast-enhanced ultrasound (CEUS) in comparison with gold standard,
i.e. triphasic CT-scan or contrast-enhanced MRI or histology.
In the differentiation between benign and malignant lesions, CEUS yielded a sensitivity of
79.4% and a specificity of 88.1%. In the subgroup of patients with cirrhosis, the kappa value
for off-site diagnosis between CEUS and reference modality was slightly lower compared to
the non-cirrhotic group: 0.42 and 0.66 (p = 0.0002), respectively. The concordance rate and
kappa value of CEUS for benign to malignant differentiation between on-site and blinded
review were 90.2% and 0.80%, respectively, compared to 83.4% and 0.66%, respectively,
for the reference imaging technique.
These results indicate that CEUS using SonoVue is a competitive and effective diagnostic
tool for the characterisation of focal liver lesions compared to other modalities such as CT
and MR imaging.
 2008 Elsevier Ltd. All rights reserved.1. Introduction
Worldwide, ultrasound is the first imaging modality for
screening focal liver lesions in various situations such as
abdominal pain, dyspeptic syndrome or cancer staging. Be-
cause of either patient or technical limitations, the sensitivity
of conventional sonography remains poor (between 55% and
70%)1,2 and generally lower than with other modalities such
as Computed Tomography (CT) or Magnetic Resonance Imag-
ing (MRI).3 Moreover, once a lesion has been detected, the
foremost question is always the differentiation of benign or
malignant lesions. These limitations are reinforced by the
non-specific ultrasound pattern of focal liver lesions even
when using modern methods including harmonic, com-
pounding or Doppler imaging. The higher accuracy reported
with CTand MRI is partly related to the use of contrast agents
which allows the description of specific vascular patterns
whatever the tissue specificity is. The use of contrast agents
is therefore pivotal in the detection and the characterisation
processes, whatever the imaging modality is.
The characterisation of focal liver lesions using the imag-
ing faces many challenges due to the high incidence of
lesions incidentally discovered during abdominal examina-
tions, limited access to some imaging techniques, cost,
patient compliance and its efficiency.
Another frequent limitation reported for conventional
sonography is reliability and reproducibility described as
operator-dependant. On the contrary, CT and MR techniques
are known for their high reliability and their easy review for
further comparison. The US limitation is related to many
factors, including inappropriate delineation in terms of
limits or contrast, poor lesion identification on still images,
absence of standard cineloops for review of complete
examination, differences between machine performancesand display as well as its dependence on operator experi-
ence. Sonography is often limited to the detection of abnor-
malities in the general population whilst CT or MRI is used
at a second stage to confirm the diagnosis and thus guides
the treatment.4
The combined development of ultrasound contrast agents
and non-linear imaging at low acoustic power has improved
diagnostic imaging accuracy .5 Real-time imaging has greatly
simplified the scanning technique making it comparable to
conventional US. Moreover, the improved contrast to tissue
ratio between the lesion itself and the surrounding tissue,
and the possibility of studying the contrast kinetics have al-
lowed the detection and characterisation of lesions not visible
or poorly visible on either conventional sonography or other
modalities. In the recent years, an increasing interest6–15 on
the use of CEUS has been reinforced by the publication of
the European EFSUMB guidelines for contrast agents in ultra-
sound.16 However, the number of multicentre studies is lim-
ited, and the lack of pharmaco-economical studies remains
a problem.
The main aim of this multicentre prospective study was to
determine the clinical value of SonoVue injection for the
characterisation of liver nodules detected incidentally but
not fully characterised by conventional US or CT-scan.
2. Subjects and methods
A total of 874 consecutive patients, involving 1034 nodules
with adequate imaging, were included in this multicentre
prospective study between May 2005 and December 2007.
Fifteen radiology centres with expertise in liver imaging
participated in the trial (Table 1). The patient population char-
acteristics were as follows: 438 females and 436 males mean
age 55.7 +/– 17.9 years and mean body weight 71.2 +/–
Table 1 – Total number of patients and nodules per centre involved in this study
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according to Ethical Committee approval. The study was
sponsored by a national grant from French Health Ministry.
The inclusion criteria were the presence of one to three li-
ver lesions with a diameter between 5 and 100 mm not fully
characterised by conventional US or previous single-phasic
CT-scan and the availability of a gold standard, i.e. an imaging
examination (three or four phase contrast-enhanced CT or
contrast-enhanced MR imaging within 30 d) or pathology
(biopsy or surgical specimen within 6 months).
The diagnostic judgements were obtained by off-site diag-
nosis, performed by two independent senior radiologists for
CEUS and one independent senior radiologist for the refer-
ence modality, blinded to the final on-site diagnosis.
A gold standard diagnosis was obtained for 862 nodules: in
184 nodules (21.3%), the diagnosis was based on histology. For
the remaining 172 nodules, no data were available due to
missing examinations (n = 54) or non-readable examinations
(n = 65).
Amongst the 862 nodules with a gold standard, 129 exam-
ined with CEUS were excluded (CEUS not performed or of
poor quality or no visible lesions) thus leading to a cohort of
733 nodules with both examinations (Table 2).
3. US imaging technique
US scanning was performed by physicianswith more than ten
years experience of liver imaging using the Sequoia 512 scan-
ner (Siemens-Acuson, CA, USA) with a curved 4C1 transducer
and CPS mode (487 examinations) or Aplio scanner (Toshiba,
Japan) with 6C1 transducer and pulse subtraction imaging
or VRI modes (348 examinations). The remaining 39 examin-
ations were performed on various scanners (Logiq9, GE, USA;
Elegra and Antares, Siemens, USA; IU22, Philips, USA). Prior to
contrast-enhanced imaging, all patients underwent conven-
tional sonography with fundamental or tissue-harmonicmodes using optimised settings for B-mode and Doppler
imaging. One or two cineloops were stored.
After completion of the baseline scanning, one or two bo-
luses of SonoVue Bracco, Italy (2.4 ml each) per nodule were
injected intravenously each followed by a 5 ml normal saline
flush. A time-delay of 10 min was observed when two injec-
tions were required for the same nodule to allow microbub-
bles to wash out.
Real-time contrast-enhanced scanning using low MI tech-
niques was started as soon as the contrast agent was injected
and was terminated when the contrast had disappeared, i.e.
from 4.5 to 7 min. Three cineloop recordings were obtained
during enhancement and stored for blinded review: the first
one between 5 and 35 s, the second one between 60 and 90 s
and the last one between 150 and 180 s after injection. Single
frames and cineloops were stored on hard disk in DICOM for-
mat, and compressed to MPEG4 for further review.
4. Image interpretation
The number, size and location of liver lesions were docu-
mented on schematic liver charts using the Couinaud classi-
fication in order to match with the lesion identified by the
reference modality.
The characterisation of focal liver lesions (FLL’s) was per-
formed according to the criteria defined by the Consensus
Conference in Rotterdam.16
On-site diagnosis was performed by a senior radiologist at
the time of the examination, and was based on the review of
both baseline and CEUS examination. Off-site diagnosis was
performed by two independent senior radiologists blinded
to the final on-site diagnosis and the reference modality.
The only data available for blinded reviewers were the indica-
tion for the examination and the location of the FLL, as drawn
by the on-site investigator on the liver chart. The blinded
reviewers were chosen amongst the principal investigators
Table 2 – Number of patients and number of nodules studied
878 patients enrolled 
16 patients with 
three nodules 
128 patients with two 
nodules
730 patients with 
one nodule 
874 patients 
1034 nodules studied 
4 patients consent 
withdrawn
Table 3 – Main Lesions Characteristics: largest diameter,
depth relative to the skin and volume of SonVue
injected by lesion.
Available data Mean SD
Diameter (mm) 1031 29.67 20.68
Skin-lesion distance (cm) 1005 5.93 2.65
Injected volume (ml) 1034 3.10 1.20
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towns. In the case of discrepancy between the two blinded
reviewers, a final consensus diagnosis was obtained by an ex-
pert committee including 5 senior radiologists.
5. Reference imaging
CT-scan and MRI were performed according to up-to-date
optimised protocols. The multidetector CT examination in-
cluded at least three phases, one acquired before contrast
administration and two acquired after injection of an
iodinated contrast agent with low osmolarity (2 ml/kg bw,
350 mg/ml) administered at a rate of 3 ml/s. The acquisition
during the arterial phase started 20–30 s after injection, or
was synchronised with a bolus tracking technique. It was fol-
lowed by a portal-venous phase acquisition starting 60–70 s
after the start of the injection. The collimation did not exceed
5 mm, and the pitch was adapted to cover the entire abdomen
within a single breath-hold.
The MR imaging protocol included at least a T2-weighted
spin-echo sequence, a T1-weighted spin-echo or gradient-
echo sequence and a dynamic T1-weighted gadolinium-
enhanced study during a breath-hold. Post-contrast arterial,
portal and delayed scans were acquired. The slice thickness
was below 8 mm, and the inter-slice gap was limited to below
20% of the slice thickness.Both examinations were interpreted on-site by an experi-
enced radiologist blinded to sonographic findings. The size,
location and type of each lesion was documented on the ana-
tomical map. Each reference examination was reviewed blind
off-site by a senior radiologist with information limited to
examination indications and subject description.
The indication for pathology (by either US or CT guided
biopsy or surgery) was based on the medical history and the
on-site image findings, and was not influenced by the con-
trast-enhanced US study.
Off-site reference imaging diagnosis, CEUS diagnosis and
pathology were obtained for 121 focal lesions.
6. Examination cost
We compared the examination costs of the three imaging
modalities on the basis of reported costs from French
health system. In this perspective, we considered the costs
for examination, injection and contrast agent. For CT-scan
and MRI, an extra value was considered for technical lump
sum.
7. Data analysis and statistical evaluation
The characterisation provided by off-site reviewers of CEUS
images was compared to the final diagnosis obtained by refer-
ence modality. When pathology was available, this modality
was considered as the reference technique irrespective of
the results of CT-scan or MRI.
Both on-site CEUS and reference imaging diagnosis were
compared to off-site CEUS and reference imaging diagnosis.
Sensitivity and specificity were calculated for each type of
lesion with a confidence interval of 95%.
The assessment of inter-reviewer concordance was evalu-
ated using concordance rate and kappa value with a confi-
dence interval of 95%. A statistically significant level was
p < 0.05.
Table 4 – Concordance of results: contrast-enhanced ultrasound (CEUS) versus Reference modality (CT-scan, MRI,
histology) Legend: Hem (Haemangioma), FNH (Focal Nodular Hyperplasia), F Fatty S (Focal Fatty Sparing), F Fatty L (Focal
Fatty Liver), Ade (Hepatocellular Adenoma), Reg N (Regenerative Nodule), HCC (HepatoCellular Carcinoma), Met
(Metastasis), Chol (Cholangiocarcinoma)
Biopsy/MRI/CT
Cyst Hem FNH F Fatty S F Fatty L Ade Reg N Abscess HCC Met Chol
C E U S Cyst 12 0 0 0 0 0 0 0 2 2 0
Hem 5 123 4 2 6 0 1 0 8 11 0
FNH 1 4 113 2 3 12 0 0 8 4 0
F Fatty S 0 2 3 4 0 0 0 0 1 1 0
F Fatty L 0 3 0 1 11 2 2 0 1 1 0
Ade 0 1 10 0 0 2 0 0 1 1 0
RegN 0 0 1 1 2 0 14 1 16 1 1
Abscess 0 0 0 0 0 0 0 5 0 1 0
HCC 1 0 4 0 0 3 9 1 120 4 3
Met 2 10 2 2 3 1 0 1 13 107 1
Chol – – – – – – – – – – –
Table 5 – Comparison between on-site and blinded off-
site MRI/CT imaging assessments
MRI/CT on-site
Malignant Benign Total
Blinded review MRI/CT Malignant 286 74 360
Benign 64 408 472
Total 350 482 832
Table 6 – Comparison between on-site and blinded off-
site CEUS imaging assessments.
CEUS on-site
Malignant Benign Total
Blinded review CEUS Malignant 316 37 353
Benign 50 488 538
Total 366 525 891
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The final diagnosis obtained by the reference modality (off-
site review) was hepatocellular carcinoma (n = 172), haemang-
ioma (n = 144), focal nodular hyperplasia (n = 137), metastasis
(n = 135), fat and focal fatty sparing area (n = 38), regenerative
nodule (n = 27), cysts (n = 24), hepatocellular adenoma (n = 21),
abscess (n = 8) and cholangiocarcinoma (n = 5).
The mean size of the nodules was 29.67 ± 20.68 mm. The
mean depth relative to skin surface was 59.30 ± 26.50 mm. A
maximum of 4.8 ml of SonoVuewas injected to characterize
a nodule with a mean dose of 3.1 ± 1.2 ml (Table 3).
For the differentiation between benign and malignant le-
sions, CEUS yielded a sensitivity of 79.4% [min 74.6, max
83.7] and a specificity of 88.1% [min 84.8, max 91]. When the
four main liver lesions (haemangioma, focal nodular hyper-
plasia, metastasis and hepatocellular carcinoma) are consid-
ered, the sensitivity was 85.4%, 82.5%, 79.3% and 69.8%,
respectively, and the specificity was 93.7%, 94.3%, 92.5% and
94.7%, respectively (Table 4).
The concordance and kappa value of CEUS for benign to
malignant differentiation between on-site and blinded review
were 90.2% [88.1–92.1] and 0.80 [0.76–0.84], respectively, com-
pared to 83.4% [80.7–85.9] and 0.66 [0.61–0.71], respectively, for
the reference imaging technique (Tables 5 and 6). The concor-
dance between reviewers 1 and 2 in the assessment of CEUS
diagnosis was 86% [min 83.5, max 88.3], and the kappa value
was 0.71 [min 0.7141, max 0.7144].
The concordance and kappa value of CEUS for the charac-
terisation of each liver lesion between on-site and blinded re-
view were 80.7% [min 77.8, max 83.4] and 0.77 [min 0.73, max
0.80], respectively, compared to 72.5% [min 69.3, max 75.6]
and 0.67 [min 0.63, max 0.70], respectively, for reference imag-
ing technique. The concordance between reviewers 1 and 2 in
the assessment of CEUS diagnosis was 71.4% [min 68.1, max
74.5], and the kappa value was 0.65 [min 0.6530, max 0.6532].
In the subgroup of patients with available pathology, the
concordance rate and kappa valuewere not different for CEUS
[64.5% (min 55.2, max 73.0) and 0.53; (min 0.42, max 0.63),
respectively] and the reference imaging technique [67.8%
(min 58.7, max 76.0) and 0.58; (min 0.47, max 0.68),
respectively].In the subgroup of patients with cirrhosis, the kappa value
for off-site diagnosis between CEUS and reference modality
was slightly decreased compared to the non-cirrhotic group:
0.42 and 0.66 (p = 0.0002), respectively, whilst concordance
rates remained similar, 71.8% [64.9–78.0] versus 73.5% [69.4–
77.3] (p = 0.65), respectively.
The reported costs are slightly lower for CEUS than for CT-
scan, and are largely lower for MR in relation to a marked dif-
ference in the technical lump sum between CT-scan and MRI
(Table 7).
9. Discussion
The introduction of US contrast agents has changed the
impact of liver ultrasonography by increasing the number of
lesions correctly detected and characterised thus reaching
the level of other imaging modalities.6–15 These observations
make the US a valuable initial imaging modality, as currently
used, as well as a cheap technique able to provide a complete
Table 7 – Comparison of the total costs for the three
imaging modalities, CEUS, CT-scan and MRI
Costs (in €) CEUS CT-scan MRI
Exam 75.60 61.55 69
Injection 9.60 9.60 9.60
Contrast agent 70 20 30
Technical lump sum 100.50 213.70
Total cost 155.20 191.65 322.30
Total costs are determined on the basis of reported costs from
French health system considering the costs for examination,
injection and contrast agent A specific additional technical lump
sum was added for CT-scan and MRI.
14 E J C S U P P L E M E N T S 6 ( 2 0 0 8 ) 9 –1 5diagnosis in one session without irradiation in anxious
patients after the discovery of a liver lesion.
The results obtained in this study are similar to the previ-
ously reported single center series17–23 with a tendency to
lower sensitivity and specificity. The first explanation would
be that this is a multicentre study in which all physicians
do not have the same experience in performing ultrasound
examinations with contrast agents. Some have an extensive
experience with more than 1000 examinations performed,
whilst others have recently acquired an experience based
on fewer than 300 exams. This might explain the discrepancy
of acquisitions. Secondly, there were some differences in the
settings or performance of various machines used in this
study related to body habitus or lesion types, which could ex-
plain some differences in the review process. A final explana-
tion would be that the results are based on a strict off-site
review process which reduces the final performances of the
method under evaluation. Despite a strict acquisition proto-
col, it appears that an off-site review process is more critical
for blinded reviewers in comparison to an on-site interpreta-
tion in relation to the difficulty in reviewing an examination
which was not performed personally and to the various image
presentations from various machines or centres.
When examining individual lesions, it is possible to appre-
ciate the role of CEUS in the diagnostic process. The high sen-
sitivity implies that only a few diagnoses were not achieved
using a contrast agent but the specificity was very high what-
ever the lesion type was. This indicates that, even in difficult
patients, using CEUS, diagnosis is valid in more than 90% of
cases with a very high specificity.
One important point is the reliability of the CEUS method
compared to previously recommended methods such as con-
trast-enhanced CT or MRI. Ultrasound is a real-time method
with strong advantages in terms of ease and cost, but it suf-
fers from some limitations in terms of difficulty in reviewing
a diagnosis on the basis of single frames with limited location
landmarks and variability in machine settings. All these fac-
tors play a role in the limited use of conventional sonography
for focal liver lesion diagnosis. The strong improvement in
characterisation obtained by the use of contrast agents may
emphasise the value of this method in place of the more
expensive and less available imaging techniques as soon as
the reliability of CEUS is validated.
The results demonstrate that concordance and kappa val-
ues between on-site and blinded off-site reviews are alwaysbetter with CEUS than with CT or MRI both in global popula-
tion or by types of lesions. Until now, the performances of
both examinations were only evaluated to underline the high
accuracy of CEUS based on contrast-kinetic studies in arterial
and late phase20 or to show comparable performances of the
two methods, but with higher specificity by CEUS.24 However,
Kim et al.6 have observed that inter-observer agreement was
markedly improved by the use of contrast, kappa value being
only 0.66 for conventional sonography but reached 0.92 for
CEUS. In a multicentre study involving 127 patients Leen
et al.17 reported a reduced inter-observer variability by using
CEUS as assessed by a high kappa value of 0.66–0.77.
Some points need to be underlined to explain these re-
sults. The first concerns the diagnostic criteria used which
were defined by the Rotterdam Consensus Conference.16 This
implies that the same criteria were used by all investigators,
thus reinforcing the diagnostic value of CEUS compared to
conventional sonography in which diagnosis is more operator
dependent. The second is that the variability between the ma-
chines used is lower when using contrast agents. Despite
some differences in bubble detection sensitivity, the enhance-
ment patterns are clearly seen leading to complete character-
isation of a lesion. If these patterns are not observed, then no
diagnosis is provided, but this is true for all the investigators.
The third concerns the strict study protocol in which precise
settings and recordings were initially defined for all methods.
This is probably a key point in ultrasound examinations
which are frequently too dependent on the physicians exper-
tise and the stored frames. Clip storage allows a true review of
the lesion which helps in the assessment of enhancement
patterns. Moreover, this storage allows an appreciation of
the relationship between the lesion and its environment as
well as differences in enhancement.
Despite the recommendations, it appears critical to review
the images provided by CT or MRI due to differences in the
machine settings, sequence and local practice. This could
influence the variability observed between on-site and
blinded reviewer. In some cases, on-site diagnosis from one
modality could be influenced by the results obtained by the
other modality.
To our knowledge, this is the first time that ultrasound has
been shown to be more reliable than CT or MR techniques in
the assessment of focal liver lesion. These results confirm
that standardisation is essential to improve diagnostic quality
and reproducibility. In the past, standardisation was less
common with conventional sonography, but current appro-
priate storage capacity and precise diagnostic criteria have in-
creased the diagnostic accuracy of ultrasound. For these
reasons, it now seems appropriate to include ultrasound in
the list of reference modalities for an accurate diagnostic
algorithm of focal liver lesion characterisation. This will
markedly modify our current strategy by promoting a single
session diagnosis, i.e. conventional sonography and CEUS
leading to cost savings and reduced delays in patient
management.
The presence of cirrhosis results in a slight decrease in
CEUS performance. In a group of 171 non-cirrhotic patients
the contrast-late phase provided a high accuracy whereas
in cirrhotic patients the arterial phase was related to the dif-
ferent types of lesions.4 However, CEUS identified a high
E J C S U P P L E M E N T S 6 ( 2 0 0 8 ) 9 –1 5 15number of hepatocellular carcinomas with a high specific-
ity.6,22,25 This suggests that CEUS can be used in all patients
with cirrhosis as soon as a nodule is detected by conven-
tional ultrasound (as also pointed out in the Barcelona
recommendations).
10. Conclusion
This study clearly indicates that CEUS using SonoVue and
the most recent contrast-specific softwares is an effective
diagnostic tool for focal liver lesion characterisation in the
place of other modalities such as CT and MR imaging. The
high reliability of this method related to high standardisation
and well-defined criteria reinforces the place of ultrasound
methods in the diagnostic algorithm. This study underlines
the need for specific training and method standardisation to
guarantee high quality examination.
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